JPH10287550A - Preparation for external use for skin - Google Patents

Preparation for external use for skin

Info

Publication number
JPH10287550A
JPH10287550A JP9216097A JP9216097A JPH10287550A JP H10287550 A JPH10287550 A JP H10287550A JP 9216097 A JP9216097 A JP 9216097A JP 9216097 A JP9216097 A JP 9216097A JP H10287550 A JPH10287550 A JP H10287550A
Authority
JP
Japan
Prior art keywords
skin
external preparation
preparation
ingredient
skin according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP9216097A
Other languages
Japanese (ja)
Inventor
Hideoki Ogawa
秀興 小川
Mikio Miyahara
幹夫 宮原
Kaoru Endo
薫 遠藤
Toshiyuki Aoki
敏之 青木
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
NIPPON RIDEIA ORIRII KYOKAI
Original Assignee
NIPPON RIDEIA ORIRII KYOKAI
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by NIPPON RIDEIA ORIRII KYOKAI filed Critical NIPPON RIDEIA ORIRII KYOKAI
Priority to JP9216097A priority Critical patent/JPH10287550A/en
Publication of JPH10287550A publication Critical patent/JPH10287550A/en
Pending legal-status Critical Current

Links

Landscapes

  • Medicinal Preparation (AREA)

Abstract

PROBLEM TO BE SOLVED: To obtain a weakly irritant preparation for external use for skin, effective for treatment of atopic dermatitis, by using a biological ingredient(s) as a moisturizing ingredient(s) and making its (their) compounding amount(s) as small as possible, and also, adjusting the pH of the preparation at the same level as that of the healthy skin. SOLUTION: This preparation contains moisturizing ingredient(s) (0.1-20 wt.%), an electrolyte ingredient (0.02-1.0 wt.%) and pH-adjustor(s) (0.1-1.0 wt.%). As the moisturizing ingredient(s), one or more kinds are preferably selected from the group consisting of saccharides (preferably, glucose, lactose, etc.), polyhydric alcohols (preferably, glycerol), high molecular polymers (preferably, polyethylene glycol polymers), polysaccharides (preferably, hyaluronic acid, chondroitin sulfate, etc.) and/or salts thereof. As the electrolyte component, sodium chloride, calcium chloride, etc., is preferable. As the pH-adjustor(s), one or more kinds are preferably selected from phosphoric acid, sodium phosphate, citric acid and sodium citrate.

Description

【発明の詳細な説明】DETAILED DESCRIPTION OF THE INVENTION

【0001】[0001]

【発明の属する技術分野】本発明は、皮膚外用剤、さら
に詳しくは、アトピー性皮膚炎等の敏感肌用の皮膚外用
剤に関する。
The present invention relates to an external preparation for skin, and more particularly, to an external preparation for sensitive skin such as atopic dermatitis.

【0002】[0002]

【従来の技術】最近、生活環境の変化や食生活の変化等
にともない、アトピー性皮膚炎は小児期以降の成人にお
いても増加している。
2. Description of the Related Art Recently, atopic dermatitis has been increasing in adults after childhood due to changes in living environment and dietary habits.

【0003】成人型アトピー性皮膚炎の発症原因は未だ
未解明の部分が多く、免疫系の異常のほかに、皮膚の乾
燥といった皮膚のバリアー機能の低下も認められてい
る。
[0003] The causes of adult atopic dermatitis are still largely unknown, and in addition to abnormalities in the immune system, a decrease in skin barrier functions such as dry skin has been observed.

【0004】一般に、こうした症状に対し、種々の抗炎
症剤の他に保湿剤配合のクリームやワセリンなどが使用
されている。
[0004] In general, creams containing a humectant, vaseline, and the like are used in addition to various anti-inflammatory agents for such symptoms.

【0005】[0005]

【発明が解決しようとする課題】しかし、患者のなかに
はこれら油性基剤により「かゆみ」「発赤」などの不適
合をおこすケースも少なくない。
However, in some patients, these oily bases cause incompatibility such as "itching" and "redness".

【0006】又、強酸性水や消炎剤を配合したローショ
ン剤も用いられているが、強い酸性や薬剤そのものの刺
激等により皮膚安全性の面で好ましくない。
A lotion containing strong acid water or an anti-inflammatory agent is also used, but it is not preferable in terms of skin safety due to strong acidity and irritation of the drug itself.

【0007】本発明は、このような問題点を解決するた
めになされたもので、アトピー性皮膚炎の予防又は症状
改善に有用な低刺激性の皮膚外用剤を得ることを課題と
する。
[0007] The present invention has been made to solve such problems, and has as its object to provide a hypoallergenic topical skin preparation useful for preventing or improving symptoms of atopic dermatitis.

【0008】[0008]

【課題を解決するための手段】すなわち、本発明は、上
記課題を解決するために、皮膚外用剤の配合成分として
生体成分を使用し、かつその配合量はできるだけ少量に
抑えるとともに、pHを健常皮膚と同じに調整すること
に着目してなされたものである。
That is, in order to solve the above-mentioned problems, the present invention uses a biological component as a compounding component of an external preparation for skin, suppresses the compounding amount as small as possible, and adjusts the pH to a normal level. The focus was on making the same adjustment as the skin.

【0009】本発明者らは、皮膚のpHと皮膚ブドウ球
菌数に着目し、アトピー性皮膚炎患者の皮膚のpH、皮
疹の重症度および皮膚ブドウ球菌数を測定し、健常人の
それと比較した。
The present inventors focused on the pH of the skin and the number of staphylococci in the skin, and measured the pH of the skin, the severity of the eruption and the number of staphylococci in the skin of patients with atopic dermatitis, and compared them with those of healthy individuals. .

【0010】その結果、アトピー性皮膚炎患者において
は、皮膚pHが健常人に比較して上昇しており、それが
皮疹の重症度および皮膚表面の黄色ブドウ球菌数に比例
していることがわかった。測定結果を表1および表2に
示す。
[0010] As a result, it has been found that in patients with atopic dermatitis, the skin pH is higher than in healthy subjects, which is proportional to the severity of the eruption and the number of Staphylococcus aureus on the skin surface. Was. Tables 1 and 2 show the measurement results.

【0011】[0011]

【表1】 [Table 1]

【0012】[0012]

【表2】 [Table 2]

【0013】以上の新しい知見より、pHが健常皮膚と
同様で、生体の汗に組成が近く、かつ感作性、刺激性の
低い皮膚外用剤が、アトピー性皮膚炎の症状を改善でき
ることを見いだし、本発明を完成した。
From the above new findings, it has been found that an external preparation for skin having a pH similar to that of healthy skin, having a composition close to that of the body's sweat, and having low sensitizing and irritating properties can improve the symptoms of atopic dermatitis. Thus, the present invention has been completed.

【0014】すなわち、本発明の皮膚外用剤は、保湿成
分を0.1〜20重量%、電解質成分を0.02〜1.
0重量%、pH調整剤を0.1〜1.0重量%含有する
ことを特徴とする。
That is, the external preparation for skin of the present invention contains 0.1-20% by weight of a moisturizing component and 0.02-1.
It is characterized by containing 0% by weight and 0.1 to 1.0% by weight of a pH adjuster.

【0015】ここで保湿成分としては、グリセリン等の
多価アルコール、ポリエチレン高重合体等の高分子、グ
ルコース、ラクトース、マルトース等の単糖類もしくは
二糖類、ヒアルロン酸、コンドロイチン硫酸等の多糖
類、電解質成分としては、ナトリウム塩、カリウム塩等
のアルカリ金属塩、カルシウム塩等のアルカリ土類金属
塩、pH調整剤としては、リン酸、クエン酸、及びその
塩類があげられる。
Examples of the moisturizing component include polyhydric alcohols such as glycerin, macromolecules such as polyethylene polymers, monosaccharides or disaccharides such as glucose, lactose and maltose, polysaccharides such as hyaluronic acid and chondroitin sulfate, and electrolytes. Components include alkali metal salts such as sodium salts and potassium salts, alkaline earth metal salts such as calcium salts, and examples of pH adjusters include phosphoric acid, citric acid, and salts thereof.

【0016】アトピー性皮膚炎の皮膚機能の特徴から、
保湿成分として生体と同じ成分を使用することにより刺
激や異物(抗原)に対する反応を抑制し、かつ配合成分
量はできるだけ少なくする必要があるため、かかる保湿
成分の好適な配合量は、0.1〜15重量%である。
From the characteristics of the skin function of atopic dermatitis,
Since the use of the same component as the living body as a moisturizing component suppresses the reaction to irritation and foreign substances (antigen), and the amount of the compounding component needs to be as small as possible, the preferable compounding amount of such a moisturizing component is 0.1 1515% by weight.

【0017】本発明の皮膚外用剤のもう一つの必須成分
であるpH調整剤は、リン酸、クエン酸およびそれらの
塩類であるが、望ましくは、リン酸およびその塩が0.
1〜0.5重量%および0.2〜1.0重量%で、pH
を4.0〜4.5望ましくは4.2〜4.4に調整した
ものである。
The pH adjusting agent, which is another essential component of the external preparation for skin of the present invention, is phosphoric acid, citric acid and salts thereof.
1-0.5 wt% and 0.2-1.0 wt%, pH
Is adjusted to 4.0 to 4.5, preferably 4.2 to 4.4.

【0018】[0018]

【作用】本発明は、健常皮膚に近いpHをアトピー性皮
膚炎に使用することにより、健常な皮膚が持つ本来の皮
膚清浄能を与え、皮膚黄色ブドウ球菌の増殖を抑制する
とともに、皮膚に適度な水分と保湿を与え、アトピー性
皮膚炎の症状を改善させる作用を有する。
According to the present invention, the use of a pH close to that of healthy skin for atopic dermatitis gives the original skin cleansing ability of healthy skin, suppresses the growth of S. aureus dermatitis, and gives the skin an appropriate It has an effect of giving a good moisture and moisturizing and improving the symptoms of atopic dermatitis.

【0019】この様な本発明の皮膚外用剤の効果を得る
には、本発明の外用ローションを1日数回、好ましくは
4〜5回炎症の起こっている部位およびその近傍に塗布
すればよい。
In order to obtain the effect of the external preparation for skin of the present invention, the topical lotion of the present invention may be applied several times a day, preferably 4 to 5 times, to a site where inflammation occurs and the vicinity thereof.

【0020】[0020]

【実施例】以下、本発明の実施例について説明する。Embodiments of the present invention will be described below.

【0021】実施例1 本実施例では、下記に示す処方に基いてローション剤を
作成した。具体的にはA成分を水19.3重量部、B成
分を水67.95重量部に完全に溶解した後、AにBを
徐々に加えて攪拌し、ローションを得た。 尚、各成分の数値は重量部を表す。
Example 1 In this example, a lotion was prepared based on the following formulation. Specifically, after completely dissolving the A component in 19.3 parts by weight of water and the B component in 67.95 parts by weight of water, B was gradually added to A and stirred to obtain a lotion. In addition, the numerical value of each component represents a weight part.

【0022】試験例1 上記実施例1のローションについて、アトピー性皮膚炎
患者を対象に使用テストを行い、患者がそれまで使用し
ていた薬剤等との有効差を試験した。
Test Example 1 The lotion of Example 1 was used for atopic dermatitis patients, and the effectiveness of the lotion was compared with the drugs used by the patients.

【0023】試験は、アトピー性皮膚炎患者59名を対
象に、顔面を左右に分け左右の一方に実施例1のローシ
ョンを外用し、他方には従来の治療を続けることとして
2週間後、主治医および患者が両者の有効差を判定する
という方法で行った。
The test was conducted on 59 patients with atopic dermatitis. The face was divided into left and right sides, and the lotion of Example 1 was applied externally to one of the left and right sides. And the patient determined the effective difference between the two.

【0024】有効差の判定は、主治医は患者がどの薬剤
を使用しているか判らない状態で有効性の判定を行なう
一重盲験試験法にて実施した。
The determination of the difference in efficacy was performed by a single blind test method in which the attending physician determined the efficacy without knowing which drug the patient was using.

【0025】試験結果は、次表3および4のとおりであ
る。主治医の判定結果は表3に、患者の判定結果は表4
にそれぞれ示す。
The test results are shown in Tables 3 and 4 below. Table 3 shows the judgment results of the attending physician, and Table 4 shows the judgment results of the patient.
Are shown below.

【0026】[0026]

【表3】 [Table 3]

【0027】[0027]

【表4】 [Table 4]

【0028】本試験結果より、本発明のローションは、
対象となった従来治療法よりも有効性が高く、主治医の
判定では中等症のアトピー性皮膚炎に5%の有意水準で
統計的に有意差を認めた。また、患者の判定において
も、重症、中等症のアトピー性皮膚炎にそれぞれ1%の
有意水準で差を認めた。
From the test results, the lotion of the present invention was
The efficacy was higher than that of the conventional treatment, and the attending physician's judgment revealed a statistically significant difference in moderate atopic dermatitis at a significance level of 5%. In addition, in the judgment of the patients, there was a significant difference of 1% between severe and moderate atopic dermatitis.

【0029】[0029]

【発明の効果】叙上のように、本発明の皮膚外用剤は、
皮膚の保湿機能を補い、皮膚を健常人本来のpHに整え
ることにより皮膚バリアー機能を回復させるため、皮膚
pHの高値およびヒト皮膚上の黄色ブドウ球菌等の常在
菌の高値を特徴とするアトピー性皮膚炎を、従来の治療
法に比べ有効に改善できる。
As described above, the external preparation for skin of the present invention comprises:
Atopy characterized by high skin pH and high levels of indigenous bacteria such as Staphylococcus aureus on human skin to restore the skin barrier function by supplementing the moisturizing function of the skin and adjusting the skin to the original pH of a healthy person. Dermatitis can be improved more effectively than conventional treatment methods.

Claims (8)

【特許請求の範囲】[Claims] 【請求項1】 保湿成分を0.1〜20重量%、電解質
成分を0.02〜1.0重量%、pH調整剤を0.1〜
1.0重量%含有することを特徴とする皮膚外用剤。
A humectant component of 0.1 to 20% by weight, an electrolyte component of 0.02 to 1.0% by weight, and a pH adjuster of 0.1 to 20% by weight.
An external preparation for skin characterized by containing 1.0% by weight.
【請求項2】 保湿成分が、糖類、多価アルコール類、
高分子重合体、多糖類及び/又はその塩から選ばれる1
種以上である請求項1記載の皮膚外用剤。
2. The moisturizing component is a saccharide, a polyhydric alcohol,
1 selected from a polymer, a polysaccharide and / or a salt thereof
2. The external preparation for skin according to claim 1, which is at least one kind.
【請求項3】 糖類が、グルコース、ラクトース、マル
トースから選ばれる1種以上である請求項2記載の皮膚
外用剤。
3. The external preparation for skin according to claim 2, wherein the saccharide is at least one selected from glucose, lactose and maltose.
【請求項4】 多価アルコール類がグリセリンである請
求項2記載の皮膚外用剤。
4. The external preparation for skin according to claim 2, wherein the polyhydric alcohol is glycerin.
【請求項5】 高分子重合体がポリエチレングリコール
高重合体である請求項2記載の皮膚外用剤。
5. The external preparation for skin according to claim 2, wherein the high polymer is a polyethylene glycol high polymer.
【請求項6】 多糖類が、ヒアルロン酸、コンドロイチ
ン硫酸、キチンから選ばれる1種以上である請求項2記
載の皮膚外用剤。
6. The external preparation for skin according to claim 2, wherein the polysaccharide is at least one selected from hyaluronic acid, chondroitin sulfate, and chitin.
【請求項7】 電解質成分が、塩化ナトリウム、塩化カ
ルシウム、塩化マグネシウムから選ばれる1種以上であ
る請求項1〜6記載の皮膚外用剤。
7. The external preparation for skin according to claim 1, wherein the electrolyte component is at least one selected from sodium chloride, calcium chloride, and magnesium chloride.
【請求項8】 pH調整剤が、リン酸及びリン酸ナトリ
ウム、クエン酸、クエン酸ナトリウムから選ばれる1種
以上である請求項1〜7記載の皮膚外用剤。
8. The external preparation for skin according to claim 1, wherein the pH adjuster is at least one selected from phosphoric acid and sodium phosphate, citric acid, and sodium citrate.
JP9216097A 1997-04-10 1997-04-10 Preparation for external use for skin Pending JPH10287550A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP9216097A JPH10287550A (en) 1997-04-10 1997-04-10 Preparation for external use for skin

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP9216097A JPH10287550A (en) 1997-04-10 1997-04-10 Preparation for external use for skin

Publications (1)

Publication Number Publication Date
JPH10287550A true JPH10287550A (en) 1998-10-27

Family

ID=14046684

Family Applications (1)

Application Number Title Priority Date Filing Date
JP9216097A Pending JPH10287550A (en) 1997-04-10 1997-04-10 Preparation for external use for skin

Country Status (1)

Country Link
JP (1) JPH10287550A (en)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1304323A1 (en) * 2000-07-19 2003-04-23 Kyowa Hakko Kogyo Co., Ltd. Preventives or remedies for atopic dermatitis
WO2003007892A3 (en) * 2001-07-07 2003-12-11 Beiersdorf Ag Cosmetic and dermatological preparations containing electrolyte, for the treatment and active prevention of dry skin and other negative changes in the physiological homeostasis of the skin
WO2008072905A1 (en) * 2006-12-13 2008-06-19 Lg Life Sciences, Ltd. Composition comprising hyaluronic acid and/or its salts for treatment of atopic dermatitis
JP2011144123A (en) * 2010-01-13 2011-07-28 Ikeda Mohando:Kk Skin care preparation
JP2018172328A (en) * 2017-03-31 2018-11-08 株式会社Cac Skin barrier enhancer, pharmaceutical composition, medical cosmetics, and cosmetic method

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1304323A1 (en) * 2000-07-19 2003-04-23 Kyowa Hakko Kogyo Co., Ltd. Preventives or remedies for atopic dermatitis
EP1304323A4 (en) * 2000-07-19 2005-01-12 Kyowa Hakko Kogyo Kk Preventives or remedies for atopic dermatitis
JP2011079856A (en) * 2000-07-19 2011-04-21 Kyowa Hakko Bio Co Ltd Preventive or remedy for atopic dermatitis
WO2003007892A3 (en) * 2001-07-07 2003-12-11 Beiersdorf Ag Cosmetic and dermatological preparations containing electrolyte, for the treatment and active prevention of dry skin and other negative changes in the physiological homeostasis of the skin
WO2008072905A1 (en) * 2006-12-13 2008-06-19 Lg Life Sciences, Ltd. Composition comprising hyaluronic acid and/or its salts for treatment of atopic dermatitis
CN101534842A (en) * 2006-12-13 2009-09-16 株式会社Lg生命科学 Composition comprising hyaluronic acid and/or its salts for treatment of atopic dermatitis
JP2011144123A (en) * 2010-01-13 2011-07-28 Ikeda Mohando:Kk Skin care preparation
JP2018172328A (en) * 2017-03-31 2018-11-08 株式会社Cac Skin barrier enhancer, pharmaceutical composition, medical cosmetics, and cosmetic method
CN110461317A (en) * 2017-03-31 2019-11-15 Cac株式会社 Skin barrier reinforcing agent, pharmaceutical composition, cosmeceutical and beauty method
EP3610863A4 (en) * 2017-03-31 2020-12-16 CAC Corporation Agent for enhancing skin barrier, medicinal composition, medicated cosmetic and beauty care method

Similar Documents

Publication Publication Date Title
EP0715852B1 (en) Use of hyaluronic acid or its salt to treat skin disease
Sneddon Adverse effect of topical fluorinated corticosteroids in rosacea
US6582709B1 (en) Cream composition comprising Dead Sea Mud
US5985918A (en) Zinc-based antiirritant creams
JPH02501739A (en) steroid lotion
JP2002053428A (en) Skin care preparation
US6051244A (en) Fructose diphosphate topical compositions
US20060269615A1 (en) Topical treatment for skin irritation
AU2002318699A1 (en) Cream for treatment of skin injured by the sun
JPH08175985A (en) Ophthalmic solution
JPH10287550A (en) Preparation for external use for skin
JPH09157171A (en) External agent for treating dermatitis
JP2006298796A (en) External preparation for improving fine wrinkle
CN115721706A (en) Composition for treating eczema dermatitis and preparation method and application thereof
CN111888275B (en) Composition and preparation method and application thereof
JP2611956B2 (en) Skin cosmetics
JPH09227387A (en) Drug externally using for treatment of atopic dermatitis
US20160235784A1 (en) Method for treating itch
JPH0977665A (en) Skin liniment
JPH09110634A (en) Skin protecting agent and its production
JP2000169327A (en) Low irritant preparation for external use for skin and bathing agent
JPH1160456A (en) Bathing agent for skin and skin preparation for external use and body soap
JP2003238333A (en) Skin preparation for external use
JPH08301773A (en) Dermal pruritus remedying agent
JP2723473B2 (en) Uses of sulfated saccharides